To Give or Not to Give Adjuvant Chemotherapy in Breast Cancer? Can CanAssist Breast Assist?

Akhade, Amol; Mathew, Aju

doi:10.1055/s-0042-1746411

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though the four GCs detailed above for prostate and breast cancer are largely validated in patients from Western countries, there has been an immunohistochemistry‐based test, called CanAssistBreast (CAB), that has been developed for breast cancer patients in India with the aim of predicting cancer recurrence. Although the lack of prospective evidence is a limitation of CAB, and although some have called into question the validity of immunohistochemistry compared to a gene expression assay, CAB has been developed and studied among Indian patients, serving as an encouraging next step 40,41 …”

Section: Challenges In Creating and Validating Genomic Classifiersmentioning

confidence: 99%

Access and barriers to genomic classifiers for breast cancer and prostate cancer in India

Ranganathan,

Dee,

Debnath

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

The incidence of cancer in general, including breast and prostate cancer specifically, is increasing in India. Breast and prostate cancers have genomic classifiers developed to guide therapy decisions. However, these genomic classifiers are often inaccessible in India due to high cost. These classifiers may also be less suitable to the Indian population, as data primarily from patients in wealthy Western countries were used in developing these genomic classifiers. In addition to the limitations in using these existing genomic classifiers, developing and validating new genomic classifiers for breast and prostate cancer in India is challenging due to the heterogeneity in the Indian population. However, there are steps that can be taken to address the various barriers that currently exist for accurate, accessible genomic classifiers for cancer in India.

show abstract

Section: Challenges In Creating and Validating Genomic Classifiersmentioning

confidence: 99%